Novartis India Ltd (NOVARTIND) — Announcement | 8 September 2026(2 announcements)
Novartis India announced an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited to market retina drugs Accentrix and Pagenax in India, involving a ₹10 crore upfront payment. The deal expands the company's ophthalmology portfolio and supports entry into a new therapeutic area, marking a strategic move to diversify its product offerings in the Indian market.
Novartis India announced an analyst and institutional investor meeting scheduled for September 11, 2026, at 4:00 pm IST, conducted virtually and in person in Mumbai, with participation confirmed via email and a note that the schedule may change; the meeting will reference only publicly available information and no unpublished price-sensitive data will be shared.
About Novartis India Ltd (NOVARTIND)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when NOVARTIND files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track NOVARTIND — Free💡 Ask AI about this filing
📊 More NOVARTIND filings
- 🔴 Announcement — 12 September 2026 Novartis India announced that the audio recording of its September 11, 2026 analyst call is now avai...
- 🔴 Announcement — 11 September 2026 Novartis India Limited announced its investor presentation for the September 11, 2026 analyst call, ...
- 🔴 Annual Report — 9 September 2026 Novartis India announced that its 78th Annual General Meeting will be held on September 24, 2026 via...
- 🟡 Board Meeting — 7 September 2026 Novartis India approved the acquisition of Pfizer's Minipress and Minipres trademarks and related IP...
- 🟡 Sustainability Report — 2 September 2026 Novartis India Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY 202...
🔥 Also filed on 8 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when NOVARTIND files new disclosures
Track NOVARTIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NOVARTIND — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd